OTCMKTS:ORGS Orgenesis (ORGS) Stock Price, News & Analysis $0.38 +0.08 (+25.00%) As of 10:07 AM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartInsider TradesSEC Filings About Orgenesis Stock (OTCMKTS:ORGS) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Orgenesis alerts:Sign Up Key Stats Today's Range$0.38▼$0.3850-Day Range$0.00▼$0.6752-Week Range$0.00▼$0.85Volume110 shsAverage Volume1,085 shsMarket Capitalization$1.94 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Orgenesis Inc. is a biotechnology company focused on cell and gene therapy development and the technologies needed to manufacture these treatments closer to the point of patient care. Its work combines therapeutic programs with bioprocessing systems intended to support the production of personalized, autologous cell therapies. The company’s technology platform includes its Point-of-Care (POCare) ecosystem and Mobile Processing Units (MPUs). These systems are designed to provide controlled, modular environments for processing patient-derived cells at hospitals, clinics, and other treatment sites, with the goal of reducing reliance on centralized manufacturing facilities. Orgenesis has pursued collaborations with academic institutions, healthcare organizations, and biotechnology partners in the United States and internationally. The company was founded in 2011, and Vered Caplan has served as its chief executive officer. Its activities have included research and development programs involving regenerative medicine and cell-based therapies, although the status and scope of individual programs may change over time. AI Generated. May Contain Errors. Read More Orgenesis Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks2nd Percentile Overall ScoreORGS MarketRank™: 0.108724128895 of 5 starsOrgenesis scored higher than 2% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for Orgenesis. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Orgenesis is -0.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Orgenesis is -0.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.10% of the float of Orgenesis has been sold short.Short Interest Ratio / Days to CoverOrgenesis has a short interest ratio ("days to cover") of 1.24, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous month Dividend0.0 / 5Dividend StrengthN/A Dividend YieldOrgenesis does not currently pay a dividend.Dividend GrowthOrgenesis does not have a long track record of dividend growth. News and Social Media0.6 / 5News Sentiment0.00 News Coverage This WeekMarketBeat has tracked 2 news articles for Orgenesis this week, compared to 0 articles on an average week.MarketBeat Follows2 people have added Orgenesis to their MarketBeat watchlist in the last 30 days. Company Ownership0.3 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Orgenesis insiders have not sold or bought any company stock.Percentage Held by Insiders1.91% of the stock of Orgenesis is held by insiders.Percentage Held by Institutions22.56% of the stock of Orgenesis is held by institutions.Read more about Orgenesis' insider trading history. Receive ORGS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Orgenesis and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ORGS Stock News HeadlinesOrgenesis (ORGS) Set to Post Quarterly Earnings on WednesdayNovember 10 at 2:57 AM | americanbankingnews.comOrgenesis (OTCMKTS:ORGS) Stock Price Breaks Below Two Hundred Day Moving Average - What's Next?November 7, 2026 | americanbankingnews.comURGENT: If you own a home, please review the map below.More than 1,300 red dots are scattered across the country, and 2,800 more are already on the way. Jim Rickards urges homeowners to check the map and see whether one is near them. Families in Georgia have been forced to sell, entire Ohio neighborhoods are being torn down, and nearly 50,000 Lake Tahoe residents face losing power. Rickards advised the Pentagon and the U.S. intelligence community for decades. He says one man outside Washington can stop it.November 13 at 1:00 AM | Paradigm Press (Ad)Orgenesis Shareholders Approve Major Charter and Stock IncreaseJune 4, 2026 | theglobeandmail.comOrgenesis Issues Alpha Warrant in New Financing DealJanuary 26, 2026 | tipranks.comOrgenesis Subsidiary Secures Convertible Loan AgreementSeptember 16, 2025 | tipranks.comOrgenesis Director Ashish Nanda ResignsAugust 25, 2025 | tipranks.comOrgenesis Faces Multiple Leadership Resignations in AugustAugust 20, 2025 | msn.comSee More Headlines ORGS Stock Analysis - Frequently Asked Questions How have ORGS shares performed this year? Orgenesis' stock was trading at $0.15 at the start of the year. Since then, ORGS shares have increased by 150.0% and is now trading at $0.3750. How were Orgenesis' earnings last quarter? Orgenesis Inc. (OTCMKTS:ORGS) issued its quarterly earnings data on Friday, August, 11th. The company reported ($1.50) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.60 by $2.10. The business had revenue of $6.98 million for the quarter. When did Orgenesis' stock split? Orgenesis shares reverse split on Wednesday, September 25th 2024.The 1-10 reverse split was announced on Monday, September 23rd 2024. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, September 24th 2024. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. Does Orgenesis have any subsidiaries? Orgenesis subsidiaries include Koligo Therapeutics, and Tamir Biotechnology Inc. How do I buy shares of Orgenesis? Shares of ORGS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Orgenesis own? Based on aggregate information from My MarketBeat watchlists, some other companies that Orgenesis investors own include NVIDIA (NVDA), Redhill Biopharma (RDHL), SoFi Technologies (SOFI), BigBear.ai (BBAI), IonQ (IONQ), Taiwan Semiconductor Manufacturing (TSM) and Micron Technology (MU). Company Calendar Today11/13/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolOTCMKTS:ORGS Previous SymbolNASDAQ:ORGS CIK1460602 Webwww.orgenesis.com Phone(480) 659-6404FaxN/AEmployees150Year Founded2008Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual Sales$662 thousand Price / Sales2.93 Cash FlowN/A Price / Cash FlowN/A Book Value($7.26) per share Price / Book-0.05Miscellaneous Outstanding Shares5,170,000Free FloatN/AMarket Cap$1.94 million OptionableNo Data Beta3.63 Social Links The Infrastructure's Backbone: 10 Stocks Powering the AI BuildoutThe AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.Get This Free Report This page (OTCMKTS:ORGS) was last updated on 11/13/2026 by MarketBeat.com Staff. From Our PartnersWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredTrump’s EO to send this $5 stock ripping higher…?President Trump's December executive order declared space a national security and economic priority, fueling a...Traders Agency | SponsoredToday's free pick (on me)Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one l...Behind the Markets | SponsoredYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | SponsoredUranium Mine Flood That Sparked a 2006 Price Surge ReturnsIn 2006, a flooded mine at Cigar Lake sent uranium prices from the $50 range to $136 in eight months. This pa...Digest Publishing | SponsoredDrop these 5 stocks before the market opens tomorrow!The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratin...Weiss Ratings | SponsoredA little-known law has been quietly applied to your savings for years.Fox News reported that under current law, legal title to most stocks and bonds sits with a central institution...Monetary Gold | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Orgenesis Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Orgenesis With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ORGS Stock Alerts